Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YH 25724

Next Previous
Drug Profile

YH 25724

Alternative Names: BI 3006337; YH25724

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yuhan
  • Developer Boehringer Ingelheim; Yuhan
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Hepatoprotectants; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Phase I Obesity
  • No development reported Hepatic fibrosis; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Hepatic-fibrosis in South Korea (SC, Injection)
  • 24 Jan 2022 Phase-II clinical trials in Non-alcoholic steatohepatitis in South Korea (SC) before January 2022 (Yuhan pipeline, January 2022)
  • 18 Jan 2022 YH 25724 is in phase I trials for Non-alcoholic steatohepatitis in South Korea (Yuhan pipeline, January 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top